Chlorocresol

Chlorocresol

SCHEMBL875121

Cc1cc(O)ccc1Cl.Oc1ccc(Br)cc1

nearest known ligand 0.76

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.52
HSD17B10 Q99714 1/20 0.46
CYP3A4 P08684 1/20 0.46
CHRM1 P11229 1/20 0.46
MAOA P21397 1/20 0.46
TBXA2R P21731 1/20 0.46
ADRA1A P35348 1/20 0.46
HTR2B P41595 1/20 0.46
ESR2 Q92731 8/20 0.43
ESR1 P03372 7/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
GLB1 P16278 1/20 0.42
CTRB1 P17538 1/20 0.42
CTRC Q99895 1/20 0.42
ALDH1A1 P00352 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chlorocresol SCHEMBL29377724 0.87
Chlorocresol SCHEMBL12344 0.87
Chlorocresol SCHEMBL6552674 0.87 HSD17B10 (0.59) ALOX15HSD17B10CYP3A4CHRM1MAOA
Chlorocresol SCHEMBL28185631 0.85 HSD17B10 (0.56) ALOX15HSD17B10CYP3A4CHRM1MAOA
Chlorocresol SCHEMBL1712039 0.85 HSD17B10 (0.56) ALOX15HSD17B10CYP3A4CHRM1MAOA
Chlorocresol SCHEMBL29353909 0.85 HSD17B10 (0.56) ALOX15HSD17B10CYP3A4CHRM1MAOA
Chlorocresol SCHEMBL1712038 0.85 HSD17B10 (0.56) ALOX15HSD17B10CYP3A4CHRM1MAOA
Chlorocresol SCHEMBL9396313 0.85 HSD17B10 (0.56) ALOX15HSD17B10CYP3A4CHRM1MAOA
Chlorocresol SCHEMBL10688541 0.83 HSD17B10 (0.50) ALOX15HSD17B10CYP3A4CHRM1MAOA
Chlorocresol SCHEMBL11041971 0.83 HSD17B10 (0.54) ALOX15HSD17B10CYP3A4CHRM1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879457-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES Ciba Specialty Chemicals Holding, Inc. (CH) 2008-01-23 EP claimed
WO-2006120135-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-11-16 WO claimed
US-20240041739-A1 BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT KLOX TECHNOLOGIES INC. (CA) 2024-02-08 US disclosed
US-11723854-B2 Biophotonic compositions and methods for providing biophotonic treatment FLE INTERNATIONAL S.R.L. (IT) 2023-08-15 US disclosed
US-20220387592-A1 BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT FLE INTERNATIONAL S.R.L. (IT) 2022-12-08 US disclosed
US-20220296713-A1 BIOPHOTONIC COMPOSITIONS FOR TREATING SKIN AND SOFT TISSUE WOUNDS HAVING EITHER OR BOTH NON-RESISTANT AND RESISTANT INFECTIONS KLOX TECHNOLOGIES LIMITED (IE) 2022-09-22 US disclosed
US-11382977-B2 Biophotonic compositions for treating skin and soft tissue wounds having either or both non-resistant and resistant infections VETOQUINOL S.A. (FR) 2022-07-12 US disclosed
US-11331257-B2 Biophotonic compositions and methods for providing biophotonic treatment KLOX TECHNOLOGIES INC. (CA) 2022-05-17 US disclosed
US-11324823-B2 Biophotonic materials and uses thereof KLOX TECHNOLOGIES INC. (CA) 2022-05-10 US disclosed
EP-3151861-B1 SILICONE-BASED BIOPHOTONIC COMPOSITIONS AND USES THEREOF KLOX TECH INC (CA) 2022-04-06 EP disclosed
US-20220023181-A1 PEROXIDE-LESS BIOPHOTONIC COMPOSITIONS AND METHODS KLOX TECHNOLOGIES LIMITED 2022-01-27 US disclosed
US-20130281913-A1 BIOPHOTONIC COMPOSITIONS AND METHODS FOR PROVIDING BIOPHOTONIC TREATMENT KLOX TECHNOLOGIES INC. (CA) 2013-10-24 US disclosed
US-20120225027-A1 TOXICITY ENHANCING COMPOUNDS AND METHODS CASE WESTERN RESERVE UNIVERSITY 2012-09-06 US disclosed
WO-2012040710-A2 STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS CASE WESTERN RESERVE UNIVERSITY (US) 2012-03-29 WO disclosed
EP-1879457-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES Ciba Specialty Chemicals Holding, Inc. (CH) 2008-01-23 EP disclosed
US-20070231295-A1 Antimicrobial Silicon Oxide Flakes CIBA SPECIALTY CHEMICALS CORP. 2007-10-04 US disclosed
WO-2006120135-A1 ANTIMICROBIAL POROUS SILICON OXIDE PARTICLES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-11-16 WO disclosed
US-20040009227-A1 Thermoplastic particles which comprise an antiviral or antimicrobial agent POREX CORPORATION 2004-01-15 US disclosed
US-20020187176-A1 Porous plastic media with antiviral or antimicrobial properties and processes for making the same POREX CORPORATION 2002-12-12 US disclosed
WO-2001065937-A1 POROUS PLASTIC MEDIA WITH ANTIVIRAL OR ANTIMICROBIAL PROPERTIES AND PROCESSES FOR MAKING THE SAME POREX TECHNOLOGIES CORPORATION (US) 2001-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070231295-A1 Antimicrobial Silicon Oxide Flakes SIK2, SIK3, SIK1 ALOX15 527/4885HSD17B10 3334/4885CYP3A4 2310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.